Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons

References

• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963–967.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016;71(5):429–435.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Yang M, Morgenthien EA, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: visit-to-visit variability and the role of 6-minute walk distance to validate changes [Abstract]. Am J Respir Crit Care Med. 2019;199:A7134.
   Google Scholar
• Nathan SD, Yang M, Morgenthien EA, et al. FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change. Eur Respir J. 2020;55(5):1902151.
   PubMed Web of Science ®Google Scholar
• Durheim MT, Collard HR, Roberts RS, et al. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015;3(5):388–396.
   PubMed Web of Science ®Google Scholar
• Paterniti MO, Bi Y, Rekic D, et al. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;14(9):1395–1402.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185(10):1044–1048.
   PubMed Web of Science ®Google Scholar
• Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest. 2014;145(3):579–585.
   PubMed Web of Science ®Google Scholar
• Esbriet (Pirfenidone) [ package insert]. South San Francisco (CA): Genentech USA, Inc; 2019 [cited 2020 Aug 12]. Available from: https://www.gene.com/download/pdf/esbriet_prescribing.pdf
   Google Scholar
• Ofev (Nintedanib) [ package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc; 2020 [cited 2020 Aug 12]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ofev/ofev.pdf
   Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Maher TM, Swigris JJ, Kreuter M, et al. Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views. Respiration. 2018;96(6):514–524.
   PubMed Web of Science ®Google Scholar
• Moore VC. Spirometry: step by step. Breathe. 2012;8(3):232–240.
   Google Scholar
• Dempsey TM, Scanlon PD. Pulmonary function tests for the generalist: a brief review. Mayo Clin Proc. 2018;93(6):763–771.
   PubMed Web of Science ®Google Scholar
• Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70–e88.
   PubMed Web of Science ®Google Scholar
• Yernault JC. The birth and development of the forced expiratory manoeuvre: a tribute to Robert Tiffeneau (1910–1961). Eur Respir J. 1997;10(12):2704–2710.
   PubMed Web of Science ®Google Scholar
• Petty TL. John Hutchinson’s mysterious machine revisited. Chest. 2002;121(5Suppl):219s–223s.
   PubMedGoogle Scholar
• American Thoracic Society. Standardization of spirometry – 1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis. 1987;136(5):1285–1298.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144(5):1202–1218.
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152(3):1107–1136.
   PubMed Web of Science ®Google Scholar
• Upagupta C, Shimbori C, Alsilmi R, et al. Matrix abnormalities in pulmonary fibrosis. Eur Respir Rev. 2018;27(148):180033.
   PubMed Web of Science ®Google Scholar
• Jacob J, Bartholmai BJ, Rajagopalan S, et al. Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis. Am J Respir Crit Care Med. 2018;198(6):767–776.
   PubMed Web of Science ®Google Scholar
• Putman RK, Gudmundsson G, Axelsson GT, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med. 2019;200(2):175–183.
   PubMed Web of Science ®Google Scholar
• Johannson KA, Vittinghoff E, Morisset J, et al. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J. 50(1):1602406. 2017.
   PubMed Web of Science ®Google Scholar
• Russell AM, Adamali H, Molyneaux PL, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(8):989–997.
   PubMed Web of Science ®Google Scholar
• Moor CC, Wapenaar M, Miedema JR, et al. A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers. Respir Res. 2018;19(1):105.
   PubMedGoogle Scholar
• Swigris J, Nathan S, Tighe R, et al. STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J. 2019;54(Suppl 63):PA1333.
   Google Scholar
• Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–157.
   PubMed Web of Science ®Google Scholar
• Jenkins RG, Simpson JK, Saini G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med. 2015;3(6):462–472.
   PubMed Web of Science ®Google Scholar
• van Cleemput J, Sonaglioni A, Wuyts WA, et al. Idiopathic pulmonary fibrosis for cardiologists: differential diagnosis, cardiovascular comorbidities, and patient management. Adv Ther. 2019;36(2):298–317.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Canepa M, Zambito PE, et al. What can we learn from pulmonary function testing in heart failure? Eur J Heart Fail. 2017;19(10):1222–1229.
   PubMed Web of Science ®Google Scholar
• Assayag D, Vittinghoff E, Ryerson CJ, et al. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109(8): 1058–1062.
   PubMed Web of Science ®Google Scholar
• Hegewald MJ, Gallo HM, Wilson EL. Accuracy and quality of spirometry in primary care offices. Ann Am Thorac Soc. 2016;13(12):2119–2124.
   PubMed Web of Science ®Google Scholar
• International Organization for Standardization. ISO 26782. Anaesthetic and respiratory equipment – spirometers intended for the measurement of time forced expired volumes in humans. Geneva (Switzerland): International Organization for Standardization; 2016.
   Google Scholar
• Du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184(12):1382–1389.
   PubMed Web of Science ®Google Scholar
• Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586–593.
   PubMed Web of Science ®Google Scholar
• Akagi T, Matsumoto T, Harada T, et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med. 2009;103(8):1209–1215.
   PubMed Web of Science ®Google Scholar
• Lin H, Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. J Thorac Dis. 2015;7(4):767–779.
   PubMed Web of Science ®Google Scholar
• Womack CJ, Harris DL, Katzel LI, et al. Weight loss, not aerobic exercise, improves pulmonary function in older obese men. J Gerontol A Biol Sci Med Sci. 2000;55(8):M453–M457.
   PubMed Web of Science ®Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179–187.
   PubMed Web of Science ®Google Scholar
• Rodriguez Moncalvo JJ, Ruiz JM, Mastroianni M, et al. Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity? Eur Respir J. 2019;54(Suppl 63):PA4703.
   Google Scholar
• Du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183(9):1231–1237.
   PubMed Web of Science ®Google Scholar
• Du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014;43(5):1421–1429.
   PubMed Web of Science ®Google Scholar